PF-00489791 For The Treatment Of Raynaud's

Back to Search
Print
Bookmark Trial

NCT01090492

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Stanford Hospital and Outpatient Center
Redwood City, California, 94063, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Raynaud's Disease, Peripheral Vascular Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Active Raynaud's Phenomenon

- Stable disease and medication requirements over the previous two months

- For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome

- both sexes

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates


- Smoking within 3 months or smoking cessation using nicotine products


- Subjects currently taking sildenafil, tadalafil or vardenafil


- Subjects with ulnar arterial occlusive disease as shown by a modified Allen test


- Pregnant or breast feeding or considering pregnancy in next 4 months


- Participation in trial for investigational drug within 30 days

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Raynaud's Disease, Peripheral Vascular DiseasePF-00489791 For The Treatment Of Raynaud's
NCT01090492
  1. Redwood City, California
  2. Farmington, Connecticut
  3. Washington, District of Columbia
  4. Atlanta, Georgia
  5. Rockford, Illinois
  6. Indianapolis, Indiana
  7. South Bend, Indiana
  8. Baltimore, Maryland
  9. Wheaton, Maryland
  10. Worcester, Massachusetts
  11. Ann Arbor, Michigan
  12. Ann Arbor, Michigan
  13. Grand Rapids, Michigan
  14. Lincoln, Nebraska
  15. New Brunswick, New Jersey
  16. Albany, New York
  17. Binghamton, New York
  18. Rochester, New York
  19. Bethlehem, Pennsylvania
  20. Duncansville, Pennsylvania
  21. Willow Grove, Pennsylvania
  22. Dallas, Texas
  23. Renton, Washington
  24. Winnipeg, Manitoba
  25. London, Ontario
  26. Ottawa, Ontario
  27. Montreal, Quebec
  28. Bogota, Cundinamarca
  29. Bogota, Cundinamarca
  30. Bogotá, Cundinamarca
  31. Bucaramanga, Santander
  32. Bucaramanga,
  33. Brno,
  34. Hradec Kralove,
  35. Praha 2,
  36. Hamburg,
  37. Budapest,
  38. Kecskemet,
  39. Szombathely,
  40. Seoul,
  41. Seoul,
  42. Seoul,
  43. Mexico, DF
  44. Guadalajara, Jalisco
  45. San Luis Potosi,
  46. Katowice,
  47. Poznan,
  48. Poznan,
  49. Wroclaw,
  50. Santiago de Compostela, A Coruña
  51. Barcelona,
  52. Madrid,
  53. Goteborg,
  54. Lund,
  55. Stockholm,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE PF-00489791 For The Treatment Of Raynaud's
Official Title  ICMJE A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon
Brief Summary The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Raynaud's Disease
  • Peripheral Vascular Disease
Intervention  ICMJE
  • Drug: PF-00489791
    Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
  • Drug: PF-00489791
    Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
Study Arms  ICMJE
  • Experimental: Secondary Raynaud 4 mg dose (period 1)
    Intervention: Drug: PF-00489791
  • Experimental: Secondary Raynaud 4 mg dose (period 2)
    Intervention: Drug: PF-00489791
  • Experimental: Secondary Raynaud 20 mg dose (period 1)
    Intervention: Drug: PF-00489791
  • Experimental: Secondary Raynaud 20 mg dose (period 2)
    Intervention: Drug: PF-00489791
  • Experimental: Primary Raynaud 4 mg dose (period 1)
    Intervention: Drug: PF-00489791
  • Experimental: Primary Raynaud 4 mg dose (period 2)
    Intervention: Drug: PF-00489791
  • Experimental: Primary Raynaud 20 mg dose (period 1)
    Intervention: Drug: PF-00489791
  • Experimental: Primary Raynaud 20 mg dose (period 2)
    Intervention: Drug: PF-00489791
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 25, 2014)		243
Original Estimated Enrollment  ICMJE
 (submitted: March 18, 2010)		208
Actual Study Completion Date  ICMJE May 31, 2011
Actual Primary Completion Date May 31, 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Active Raynaud's Phenomenon
  • Stable disease and medication requirements over the previous two months
  • For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome
  • both sexes

Exclusion Criteria:

  • Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates
  • Smoking within 3 months or smoking cessation using nicotine products
  • Subjects currently taking sildenafil, tadalafil or vardenafil
  • Subjects with ulnar arterial occlusive disease as shown by a modified Allen test
  • Pregnant or breast feeding or considering pregnancy in next 4 months
  • Participation in trial for investigational drug within 30 days
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Colombia,   Czechia,   Germany,   Hungary,   Korea, Republic of,   Mexico,   Poland,   Spain,   Sweden,   United States
Removed Location Countries Argentina,   Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01090492
Other Study ID Numbers  ICMJE A7331010
EudraCT 2010-019009-40
2010-019009-40 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP